AU2017387033B2 - Metalloenzyme inhibitor compounds - Google Patents

Metalloenzyme inhibitor compounds Download PDF

Info

Publication number
AU2017387033B2
AU2017387033B2 AU2017387033A AU2017387033A AU2017387033B2 AU 2017387033 B2 AU2017387033 B2 AU 2017387033B2 AU 2017387033 A AU2017387033 A AU 2017387033A AU 2017387033 A AU2017387033 A AU 2017387033A AU 2017387033 B2 AU2017387033 B2 AU 2017387033B2
Authority
AU
Australia
Prior art keywords
mmol
cyclopropyl
benzo
reaction mixture
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017387033A
Other languages
English (en)
Other versions
AU2017387033A1 (en
Inventor
William J. Hoekstra
Sammy R. Shaver
Steven SPARKS
Christopher M. Yates
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corxel Pharmaceuticals Hong Kong Ltd
Original Assignee
Corxel Pharmaceuticals Hong Kong Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corxel Pharmaceuticals Hong Kong Ltd filed Critical Corxel Pharmaceuticals Hong Kong Ltd
Publication of AU2017387033A1 publication Critical patent/AU2017387033A1/en
Assigned to PHASEBIO PHARMACEUTICALS, INC. reassignment PHASEBIO PHARMACEUTICALS, INC. Request for Assignment Assignors: SELENITY THERAPEUTICS (BERMUDA), LTD.
Assigned to JI XING PHARMACEUTICALS HONG KONG LIMITED reassignment JI XING PHARMACEUTICALS HONG KONG LIMITED Request for Assignment Assignors: PHASEBIO PHARMACEUTICALS, INC.
Application granted granted Critical
Publication of AU2017387033B2 publication Critical patent/AU2017387033B2/en
Priority to AU2024202860A priority Critical patent/AU2024202860A1/en
Assigned to CORXEL PHARMACEUTICALS HONG KONG LIMITED reassignment CORXEL PHARMACEUTICALS HONG KONG LIMITED Request to Amend Deed and Register Assignors: JI XING PHARMACEUTICALS HONG KONG LIMITED
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2017387033A 2016-12-29 2017-12-22 Metalloenzyme inhibitor compounds Active AU2017387033B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024202860A AU2024202860A1 (en) 2016-12-29 2024-05-01 Metalloenzyme inhibitor compounds

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662440181P 2016-12-29 2016-12-29
US62/440,181 2016-12-29
PCT/US2017/068190 WO2018125800A2 (en) 2016-12-29 2017-12-22 Metalloenzyme inhibitor compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024202860A Division AU2024202860A1 (en) 2016-12-29 2024-05-01 Metalloenzyme inhibitor compounds

Publications (2)

Publication Number Publication Date
AU2017387033A1 AU2017387033A1 (en) 2019-08-15
AU2017387033B2 true AU2017387033B2 (en) 2024-02-01

Family

ID=62709109

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017387033A Active AU2017387033B2 (en) 2016-12-29 2017-12-22 Metalloenzyme inhibitor compounds
AU2024202860A Pending AU2024202860A1 (en) 2016-12-29 2024-05-01 Metalloenzyme inhibitor compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024202860A Pending AU2024202860A1 (en) 2016-12-29 2024-05-01 Metalloenzyme inhibitor compounds

Country Status (14)

Country Link
US (3) US10085984B2 (enExample)
EP (2) EP4311577A3 (enExample)
JP (2) JP7227157B2 (enExample)
KR (1) KR102690885B1 (enExample)
CN (2) CN110691598A (enExample)
AU (2) AU2017387033B2 (enExample)
CA (1) CA3055292A1 (enExample)
DK (1) DK3562487T3 (enExample)
ES (1) ES2967119T3 (enExample)
FI (1) FI3562487T3 (enExample)
MX (2) MX2019007892A (enExample)
RU (1) RU2764666C2 (enExample)
TW (1) TWI786078B (enExample)
WO (1) WO2018125800A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104136427B (zh) * 2012-01-20 2017-03-01 威尔金制药有限公司 金属酶抑制剂化合物
EP3562306B1 (en) 2016-12-29 2025-02-26 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
RU2764666C2 (ru) 2016-12-29 2022-01-19 Селенити Терапьютикс (Бермуда), Лтд. Соединения, ингибирующие металлоферменты
AU2020207051B2 (en) * 2019-01-08 2025-07-24 Corxel Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
GB201901757D0 (en) 2019-02-08 2019-03-27 Syngenta Crop Protection Ag Herbicidal compounds
WO2021233861A1 (en) 2020-05-19 2021-11-25 Bayer Aktiengesellschaft Azabicyclic(thio)amides as fungicidal compounds
EP4165038A1 (en) 2020-06-10 2023-04-19 Bayer Aktiengesellschaft Azabicyclyl-substituted heterocycles as fungicides
AT524288B1 (de) * 2020-09-16 2024-05-15 Gatan Inc Computergestütztes Verfahren zur Bestimmung eines Elementanteiles eines Bestimmungselementes kleiner Ordnungszahl, insbesondere eines Li-Anteiles, und Vorrichtung zur Datenverarbeitung hierzu
WO2025157275A1 (zh) * 2024-01-26 2025-07-31 箕星药业香港有限公司 金属酶抑制剂化合物的固体形式
CN120463643B (zh) * 2025-05-27 2025-11-28 咸阳职业技术学院 一种2-环丙基胺基-3-硝基-6-氯吡啶的合成方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2939916A1 (de) 1979-10-02 1981-04-23 Hoechst Ag, 6000 Frankfurt Quaternierte, verbrueckte benzimidazolyl-benzimidazole, verfahren zu deren herstellung und deren verwendung
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
EP0431519B1 (en) 1989-12-04 1994-06-15 G.D. Searle & Co. System for transdermal albuterol administration
US5106863A (en) 1990-03-26 1992-04-21 Ortho Pharmaceutical Corporation Substituted imidazole and pyridine derivatives
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
DE69212850T2 (de) 1991-01-15 1997-03-06 Alcon Lab Inc Verwendung von Karrageenan in topischen ophthalmologischen Zusammensetzungen
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
WO1993011938A1 (en) 1991-12-18 1993-06-24 Minnesota Mining And Manufacturing Company Multilayered barrier structures
EP0553769B1 (de) 1992-01-29 1996-01-03 FRANZ VÖLKL GmbH & CO. SKI UND TENNIS SPORTARTIKELFABRIK KG Ballspielschläger, insbesondere Tennisschläger
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
WO2000078761A1 (en) 1999-06-23 2000-12-28 Sepracor, Inc. Indolyl-benzimidazole antibacterials, and methods of use thereof
EP1441725A1 (en) 2001-10-26 2004-08-04 Aventis Pharmaceuticals Inc. Benzimidazoles and analogues and their use as protein kinases inhibitors
BR0306785A (pt) * 2002-01-07 2004-11-09 Eisai Co Ltd Deazapurinas e seus usos
US7375228B2 (en) 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1604988A1 (en) * 2004-05-18 2005-12-14 Sanofi-Aventis Deutschland GmbH Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
KR101099303B1 (ko) 2005-01-28 2011-12-26 주식회사 대웅제약 신규한 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
AR055669A1 (es) * 2005-10-03 2007-08-29 Astrazeneca Ab Derivados de 3h - imidazo[4, 5 -b]piridina como inhibidores selectivos de gsk3, metodos e internediarios para su preparacion, composiciones farmaceuticas que los contienen y su uso para la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas y mentales.
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
AU2006311914C1 (en) 2005-11-03 2013-10-24 Chembridge Corporation Heterocyclic compounds as tyrosine kinase modulators
US20080027044A1 (en) 2006-06-13 2008-01-31 Kim Lewis Prodrug antibiotic screens
EP1878724A1 (en) 2006-07-15 2008-01-16 sanofi-aventis A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles
WO2008128968A1 (en) 2007-04-19 2008-10-30 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutamate receptor-5
US7737175B2 (en) 2007-06-01 2010-06-15 Duke University Methods and compositions for regulating HDAC4 activity
CN101687815A (zh) 2007-06-26 2010-03-31 塞诺菲-安万特股份有限公司 苯并咪唑和氮杂苯并咪唑的区域选择性铜催化合成
JP5142836B2 (ja) 2007-07-02 2013-02-13 オセ−テクノロジーズ ビーブイ 走査画像要素位置合わせ方法
EP2205070A4 (en) 2007-10-04 2011-01-12 Merck Sharp & Dohme N-HYDROXY-NAPHTHALINE-DICARBOXAMIDE AND N-HYDROXY-BIPHENYL-DICARBOXAMIDE COMPOUNDS AS HISTONDEACETYLASE INHIBITORS
AU2009212135B2 (en) 2008-02-07 2014-08-21 Massachusetts Eye & Ear Infirmary Compounds that enhance Atoh-1 expression
AR072297A1 (es) * 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
GB0821994D0 (en) 2008-12-02 2009-01-07 Ge Healthcare Ltd In viva imaging method
WO2010130796A1 (en) 2009-05-15 2010-11-18 Novartis Ag Aryl pyridine as aldosterone synthase inhibitors
ES2663351T3 (es) 2009-11-17 2018-04-12 Novartis Ag Derivados de aril-piridina como inhibidores de la aldosterona sintasa
US9382226B2 (en) * 2010-07-21 2016-07-05 Merck Sharp & Dohme Corp. Aldosterone synthase inhibitors
DK2624832T3 (en) 2010-10-08 2018-01-08 Vib Vzw HDAC INHIBITORS FOR TREATMENT OF CHARCOT-MARIE-TOOTHS DISEASE
WO2012177852A1 (en) * 2011-06-24 2012-12-27 Arqule, Inc Substituted imidazopyridinyl compounds
WO2013033901A1 (en) * 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
US9883909B2 (en) * 2012-03-08 2018-02-06 Medtronic Ardian Luxembourg S.A.R.L. Renal neuromodulation methods and systems for treatment of hyperaldosteronism
CN103626783B (zh) * 2012-08-22 2016-06-08 中国科学院上海药物研究所 双环稠杂环化合物及其用途和药物组合物
WO2014179303A1 (en) 2013-04-29 2014-11-06 The General Hospital Corporation Amyloid precursor protein mrna blockers for treating down syndrome and alzheimer's disease
MY176401A (en) * 2014-04-24 2020-08-05 Mitsubishi Tanabe Pharma Corp Novel disubstituted 1,2,4-triazine compound
WO2015188369A1 (en) 2014-06-13 2015-12-17 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
TR201907755T4 (tr) * 2014-10-15 2019-06-21 Boehringer Ingelheim Int Aldosteron sentaz inhibitörleri.
WO2018118781A1 (en) * 2016-12-20 2018-06-28 Fmc Corporation Fungicidal oxadiazoles
RU2764666C2 (ru) 2016-12-29 2022-01-19 Селенити Терапьютикс (Бермуда), Лтд. Соединения, ингибирующие металлоферменты
EP3562306B1 (en) 2016-12-29 2025-02-26 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
AU2020207051B2 (en) 2019-01-08 2025-07-24 Corxel Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MEREDITH, E.L. ET AL.: "Discovery and in Vivo Evaluation of Potent Dual CYP11B2 (Aldosterone Synthase) and CYP11B1 Inhibitors", ACS MEDICINAL CHEMISTRY LETTERS, vol. 4, no. 12, 2013, pages 1203-1207. DOI: 10.1021/ML400324C *

Also Published As

Publication number Publication date
BR112019013478A2 (pt) 2020-01-07
US10085984B2 (en) 2018-10-02
US12458642B2 (en) 2025-11-04
FI3562487T3 (fi) 2023-12-14
RU2764666C2 (ru) 2022-01-19
WO2018125800A3 (en) 2018-08-16
AU2017387033A1 (en) 2019-08-15
KR20190129034A (ko) 2019-11-19
EP3562487A2 (en) 2019-11-06
EP4311577A2 (en) 2024-01-31
TWI786078B (zh) 2022-12-11
TW201831465A (zh) 2018-09-01
AU2024202860A1 (en) 2024-05-23
MX2019007892A (es) 2020-02-05
JP2023071692A (ja) 2023-05-23
EP3562487A4 (en) 2020-08-26
CN120987917A (zh) 2025-11-21
US11040034B2 (en) 2021-06-22
ES2967119T3 (es) 2024-04-26
JP7227157B2 (ja) 2023-02-21
KR102690885B1 (ko) 2024-08-02
RU2019123854A (ru) 2021-02-01
WO2018125800A2 (en) 2018-07-05
US20190008861A1 (en) 2019-01-10
EP3562487B1 (en) 2023-11-29
RU2019123854A3 (enExample) 2021-05-12
CN110691598A (zh) 2020-01-14
DK3562487T3 (da) 2024-01-02
US20210322409A1 (en) 2021-10-21
JP2020510693A (ja) 2020-04-09
JP7611278B2 (ja) 2025-01-09
EP4311577A3 (en) 2024-04-17
US20180185362A1 (en) 2018-07-05
CA3055292A1 (en) 2018-07-05
MX2022012386A (es) 2022-11-30

Similar Documents

Publication Publication Date Title
AU2017387033B2 (en) Metalloenzyme inhibitor compounds
AU2020207051B2 (en) Metalloenzyme inhibitor compounds
US11919883B2 (en) Metalloenzyme inhibitor compounds
HK40108422A (en) Metalloenzyme inhibitor compounds
HK40017142A (en) Metalloenzyme inhibitor compounds
HK40017142B (en) Metalloenzyme inhibitor compounds
BR112019013478B1 (pt) Compostos e composições farmacêuticas, seus usos como inibidores de metaloenzima e método in vitro para inibir a atividade de metaloenzima
HK40063677B (en) Metalloenzyme inhibitor compounds
HK40063677A (en) Metalloenzyme inhibitor compounds

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: PHASEBIO PHARMACEUTICALS, INC.

Free format text: FORMER APPLICANT(S): SELENITY THERAPEUTICS (BERMUDA), LTD.

PC1 Assignment before grant (sect. 113)

Owner name: JI XING PHARMACEUTICALS HONG KONG LIMITED

Free format text: FORMER APPLICANT(S): PHASEBIO PHARMACEUTICALS, INC.

FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: CORXEL PHARMACEUTICALS HONG KONG LIMITED

Free format text: FORMER NAME(S): JI XING PHARMACEUTICALS HONG KONG LIMITED